Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 1661 to 1670 of 2671 total matches.

Apoaequorin (Prevagen) to Improve Memory

   
The Medical Letter on Drugs and Therapeutics • Nov 01, 2021  (Issue 1636)
protein found in humans.1 Dysregulation of neuronal calcium is thought to be involved in the complex ...
A synthetic form of the protein apoaequorin is the active ingredient in the over-the-counter dietary supplement Prevagen (Quincy Bioscience), which is heavily marketed to improve memory.
Med Lett Drugs Ther. 2021 Nov 1;63(1636):175-6 |  Show IntroductionHide Introduction

In Brief: Afamitresgene Autoleucel (Tecelra) for Synovial Sarcoma (online only)

   
The Medical Letter on Drugs and Therapeutics • Oct 14, 2024  (Issue 1713)
autoleucel was based on the results of an open-label trial (SPEARHEAD-1) in 44 HLA-A*02:01-03 and 06 allele ...
Afamitresgene autoleucel (Tecelra – Adaptimmune), a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T-cell immunotherapy, has received accelerated approval from the FDA for one-time treatment of adults with unresectable or metastatic synovial sarcoma who received prior chemotherapy and are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen. It is the first gene therapy to be approved in the US for treatment of synovial sarcoma. Accelerated approval of the immunotherapy was based on the...
Med Lett Drugs Ther. 2024 Oct 14;66(1713):e169-70   doi:10.58347/tml.2024.1713i |  Show IntroductionHide Introduction

Teal Wand — An At-Home Cervical Cancer Screening Device

   
The Medical Letter on Drugs and Therapeutics • Jul 21, 2025  (Issue 1733)
by high-risk human papillomavirus (HPV).1 The conventional Papanicolaou (Pap) test for cervical cytology ...
The FDA has authorized use of Teal Wand (Teal Health), an at-home vaginal sample self-collection device, for cervical cancer screening.
Med Lett Drugs Ther. 2025 Jul 21;67(1733):116   doi:10.58347/tml.2025.1733c |  Show IntroductionHide Introduction

Aspirin For Prevention Of Myocardial Infarction And Stroke

   
The Medical Letter on Drugs and Therapeutics • Aug 25, 1989  (Issue 799)
(Anturane Study Group, Lancet, 1:237, 1982). Ticlopidine (Ticlid), an investigational antiplatelet drug ...
Taking aspirin to prevent recurrence or worsening of cardiovascular disease has become a common practice in recent years (Medical Letter, 28:31, 1986). Now, the US Food and Drug Administration is considering whether aspirin can also be advertised for prevention of a first myocardial infarction in previously healthy people.
Med Lett Drugs Ther. 1989 Aug 25;31(799):77-8 |  Show IntroductionHide Introduction

Omeprazole

   
The Medical Letter on Drugs and Therapeutics • Mar 09, 1990  (Issue 813)
step in secretion of hydrogen ions into the gastric lumen (P Lindberg et al, Med Res Rev, 10:1, 1990 ...
Omeprazole (Losec - Merck), a new drug that suppresses gastric acid secretion, has been approved by the US Food and Drug Administration for short-term (four to eight weeks) treatment of severe or refractory gastroesophageal reflux and for long-term treatment of pathological hypersecretory conditions such as Zollinger-Ellison syndrome, multiple endocrine adenomas, and systemic mastocytosis. Although widely used abroad for treatment of peptic ulcers, it has not been approved for that indication in the USA.
Med Lett Drugs Ther. 1990 Mar 9;32(813):19-20 |  Show IntroductionHide Introduction

Clarithromycin and Azithromycin

   
The Medical Letter on Drugs and Therapeutics • May 15, 1992  (Issue 870)
OF SOME ANTIMICROBIALS Wholesale Drug Dosage Cost 1 Azithromycin − Zithromax (Pfizer) 500 mg, day 1 ...
Clarithromycin (Biaxin - Abbott) and azithromycin (Zithromax - Pfizer), two macrolide antibiotics chemically related to erythromycin, have been approved by the US Food and Drug Administration for treatment of respiratory, skin, and skin structure infections. Azithromycin has also been approved for treatment of nongonococcal urethritis and cervicitis caused by Chlamydia trachomatis.
Med Lett Drugs Ther. 1992 May 15;34(870):45-7 |  Show IntroductionHide Introduction

Zaleplon for Insomnia

   
The Medical Letter on Drugs and Therapeutics • Oct 08, 1999  (Issue 1063)
Onset of action dose 1 Cost 2 Triazolam − average generic price short intermediate 0.25 mg $ 4.62 ...
Zaleplon, a pyrazolopyrimidine hypnotic, was recently approved by the FDA for short-term treatment of insomia. Zaleplon, like zolpidem, is a non-benzodiazepine that binds to benzodiazepine receptors.
Med Lett Drugs Ther. 1999 Oct 8;41(1063):93-4 |  Show IntroductionHide Introduction

Mifepristone (RU 486)

   
The Medical Letter on Drugs and Therapeutics • Oct 30, 2000  (Issue 1091)
. It is generally used with misoprostol (Cytotec − Searle), an E 1 prostaglandin analog marketed in the USA only ...
Mifepristone (RU 486; Mifeprex - Danco), an antiprogestin, has been approved by the FDA for termination of intrauterine pregnancies of 49 days or less. It is generally used with misoprostol (Cytotec - Searle), an E1 prostaglandin analog marketed in the USA only for prevention of gastric ulcers.
Med Lett Drugs Ther. 2000 Oct 30;42(1091):101-2 |  Show IntroductionHide Introduction

Botulinum Toxin (Botox Cosmetic) for Frown Lines

   
The Medical Letter on Drugs and Therapeutics • May 27, 2002  (Issue 1131)
dermatology practice, about 1% of patients (4/320) receiving botulinum toxin type A injections ...
Botulinum toxin type A (Botox Cosmetic - Allergan) has received formal approval from the FDA for treatment of glabellar ("frown") lines in adults not more than 65 years old, and is being heavily advertised. Even before this approval, cosmetic use of botulinum toxin to reduce wrinkles on the face and neck had become a popular alternative to cosmetic surgery (Medical Letter 1999; 41:63). Botulinum toxin type A (Botox) and type B (Myobloc) are approved for treatment of cervical dystonia (Medical Letter 2001; 43:53), and type A has been approved since 1989 for treatment of strabismus and...
Med Lett Drugs Ther. 2002 May 27;44(1131):47-8 |  Show IntroductionHide Introduction

Peginterferon Alfa-2a (Pegasys) for Chronic Hepatitis C

   
The Medical Letter on Drugs and Therapeutics • Mar 03, 2003  (Issue 1151)
interferon. Patients with genotype 1 HCV, the most prevalent in the US, achieved SVR rates of 46% compared ...
The FDA has approved recombinant interferon alfa-2a conjugated to polyethylene glycol (Pegasys - Roche) alone or with oral ribavirin (Copegus - Roche) for treatment of adults with chronic hepatitis C virus (HCV) infections not previously treated with interferon alpha. The standard of care for treatment of most patients with hepatitis C has been once-weekly injections of peginterferon alfa-2b (PEG-Intron -Schering) plus oral ribavirin (Rebetol - Schering) (Medical Letter 2001; 43:54).
Med Lett Drugs Ther. 2003 Mar 3;45(1151):19-20 |  Show IntroductionHide Introduction